AE Wealth Management LLC Makes New $612,000 Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

AE Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 5,765 shares of the company’s stock, valued at approximately $612,000.

Several other institutional investors have also recently bought and sold shares of NBIX. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Neurocrine Biosciences by 1.9% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,430 shares of the company’s stock worth $627,000 after acquiring an additional 120 shares in the last quarter. Red Spruce Capital LLC grew its stake in shares of Neurocrine Biosciences by 0.8% in the 3rd quarter. Red Spruce Capital LLC now owns 15,203 shares of the company’s stock worth $1,615,000 after acquiring an additional 121 shares in the last quarter. Grandfield & Dodd LLC grew its stake in shares of Neurocrine Biosciences by 0.9% in the 2nd quarter. Grandfield & Dodd LLC now owns 13,927 shares of the company’s stock worth $1,360,000 after acquiring an additional 130 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Neurocrine Biosciences by 1.3% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 11,303 shares of the company’s stock worth $1,102,000 after acquiring an additional 143 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Neurocrine Biosciences by 1.2% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 12,267 shares of the company’s stock worth $1,196,000 after acquiring an additional 145 shares in the last quarter. Institutional investors and hedge funds own 92.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NBIX. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $78.00 to $101.00 in a research note on Wednesday, November 2nd. Wells Fargo & Company increased their price target on shares of Neurocrine Biosciences from $110.00 to $120.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. Citigroup increased their price target on shares of Neurocrine Biosciences from $114.00 to $128.00 and gave the company a “buy” rating in a research report on Monday, October 24th. Morgan Stanley increased their price target on shares of Neurocrine Biosciences from $102.00 to $120.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. Finally, StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 7th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $122.24.

Neurocrine Biosciences Stock Down 0.5 %

Shares of NASDAQ:NBIX opened at $108.99 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $72.28 and a twelve month high of $129.29. The firm has a market capitalization of $10.48 billion, a PE ratio of 191.21 and a beta of 0.54. The company has a 50-day moving average price of $119.23 and a two-hundred day moving average price of $109.53.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $0.69 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.15). Neurocrine Biosciences had a return on equity of 4.06% and a net margin of 4.19%. The firm had revenue of $387.90 million during the quarter, compared to analysts’ expectations of $378.05 million. Analysts anticipate that Neurocrine Biosciences, Inc. will post 1.93 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 4,923 shares of the stock in a transaction dated Thursday, October 27th. The shares were sold at an average price of $115.04, for a total value of $566,341.92. Following the sale, the insider now directly owns 29,234 shares of the company’s stock, valued at $3,363,079.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Stephen A. Sherwin sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $118.86, for a total value of $3,565,800.00. Following the sale, the director now directly owns 25,055 shares of the company’s stock, valued at $2,978,037.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Darin Lippoldt sold 4,923 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The shares were sold at an average price of $115.04, for a total transaction of $566,341.92. Following the completion of the sale, the insider now directly owns 29,234 shares in the company, valued at $3,363,079.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 144,494 shares of company stock valued at $17,608,726. 4.40% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.